The Use of App-based Follow-up of Cardiac Implantable Electronic Devices

Paul Richard Roberts and Mohamed Hassan ElRefai

University Hospital Southampton NHS Foundation Trust, Southampton, UK

Abstract
There has been a steady rise in the number of patients treated with cardiac implantable electrical devices. Remote monitoring and remote follow-up have proven superior to conventional care in the follow-up of these patients and represent the new standard of care. With the widespread availability of smartphones and with more people using them for health queries, app-based remote care offers a promising new digital health solution promoting the shift of follow-up to exception-based assessments. It focuses on patients’ enablement and has shown promising results, but also highlights the need to increase the system’s automaticity to achieve acceptable follow-up adherence rates. MyCareLink Heart is a fully automated app-based system that represents the next generation of app-based monitoring and is currently being evaluated in an international study with promising initial results.

Keywords
Remote monitoring, digital health, cardiac implantable electronic devices, enablement, smart technology, mobile app, Bluetooth, m-health, e-health, MyCareLink Smart, MyCareLink Heart

‘Digital health’ increasingly surrounds us in the clinical environment, although it is not always embraced among all healthcare professionals. Modern technologies and digital appliances have a significant impact on the way we care for patients by offering innovative ways to converge technology, connectivity and people. This should translate into improved care and clinical outcomes. The term is often used more broadly to include ‘e-health’, as well as developing areas, such as the use of advanced computer sciences in the fields of big data, genomics and artificial intelligence.

The WHO has described e-health as the cost-effective and secure use of information and communication technologies in support of health and health-related fields, including healthcare services, health surveillance, health literature, health education, knowledge and research. Currently, there is a need to adopt evidence-based practice via research with regard to digital health solutions. This can facilitate reimbursement, promote their use on a wider scale and make them more readily available.

In the US, 53% of individuals over the age of 65 years have smartphones and 62% use their smartphone for health enquiries. It has been estimated that 83% of payers and providers believe that consumers need to take more control of their health in a value-based system. Mobile wireless technologies for public health – referred to as m-health – have been shown to increase access to health information, services and skills, as well as promoting positive changes in health behaviours to prevent the onset of acute and chronic diseases. It is the responsibility of healthcare practitioners to remain up to date with available options to provide appropriate advice and guidance to our patients.

Device follow-up is a mandatory part of the care for patients treated with cardiac implantable electronic devices (CIEDs). These include permanent pacemakers (PPMs), ICDs, cardiac resynchronisation therapy (CRT) pacemakers and CRT defibrillators and implantable loop recorders. After implantation, CIEDs require close monitoring. This is a highly technical and specialised process requiring dedicated structures, equipment and the interaction of several healthcare personnel. It needs to be done in a timely manner to safely and effectively deliver therapy and is guideline driven.

There has been a steady increase in the number of patients with CIEDs. In 2016, a total of 547,586 PPMs, 105,730 ICDs and 87,654 CRTs were implanted worldwide in 53 European Society of Cardiology (ESC) member countries. Between 2007 and 2016 there was an increased rate of implantation of various CIEDs in ESC member countries. Implantation rates for PPM increased from 619 per million inhabitants in 2007 to 742 per million inhabitants in 2016, ICDs from 92 per million inhabitants in 2007 to 133 per million in 2016 and CRTs from 53 per million inhabitants in 2007 to 118 per million in 2016. This has imposed a significant burden on the already limited resources arising from their follow-up in outpatient clinics. It is estimated that the number of encounters for CIED follow-up is approximately 2.2 million per year in Europe alone. Therefore, there is a need to organise follow-up of patients with CIEDs efficiently and effectively.

Remote Follow-up and Monitoring of Cardiac Implantable Electronic Devices
Traditional follow-up of CIEDs involved patients attending clinics where their devices were interrogated using a wand-based radiofrequency
Remote follow-up of CIEDs refers to the process of routine scheduled remote device interrogations, where transmission of data occurs based on pre-specified parameters related to the device functionality and clinical events. These systems usually consist of base units that reside in the patient’s home and communicate with their device either wirelessly or using an RF-based solution. The base unit then transmits the data using either cell services or landline internet connection to the company-specific remote follow-up system. It is structured to mimic conventional in-clinic checks but provides the opportunity for alert-based interactions and more frequent follow-up with monitoring between scheduled transmissions (remote monitoring). While more frequent follow-up and more monitoring may result in an increase in the transmitted data, acting on this increasing generation of data should be driven by guidelines to reduce the risk of overuse of remote monitoring. Remote follow-up offers an opportunity to resolve some of the challenges associated with the delivery of effective CIED follow-up by improving clinic efficiency and improving the patient’s adherence to follow-up.  

Remote care (RC) has proven superior to conventional monitoring in many aspects. RC in pacemaker patients is associated with increased survival, and patients with high RC adherence have shown 53% greater survival than patients with low RC adherence and 140% greater survival compared with no RC. The Pacemaker Remote Follow-up Evaluation and Review (PREFER) study highlighted that the diagnosis of clinical actionable events – namely AF, fast ventricular rates in response to atrial arrhythmias, non-sustained ventricular tachycardia (VT), abnormal device or lead parameters and change in percentage of ventricular pacing – was higher and 26% faster in patients with RC. Furthermore, the Evaluate the Benefits of Pacemaker Follow-Up With Home-Monitoring (COMPAS) trial demonstrated that there were 66% fewer hospitalisations as a result of atrial arrhythmias and overall 56% fewer ambulatory visits for the remotely monitored pacemaker recipients. This all translates into lower healthcare expenditure in office visits in ambulatory visits for the remotely monitored pacemaker recipients. Hospitalisations as a result of atrial arrhythmias and overall 56% fewer 

A large retrospective analysis was performed in the US of more than 95,000 patients who were enrolled in the CareLink database, using MyCareLink Smart. The analysis looked into the proportion of patients who adhered to the follow-up transmissions according to the clinic schedule. There were 48,016 patients assigned app-based remote follow-up, and 40,511 (84.4%) of them activated their devices for RC. Adherence analysis was limited to 14,232 patients who activated their RC and had at least 12 months of follow-up after activation. Of these patients, 89% were considered adherent, as per Heart Rhythm Society guidelines, as they had at least one more transmission within 3 months to 1 year after activation. There was no difference in adherence to follow-up in patients having a generator change or a de novo device. There was also no difference between men and women. The high
The first generation of app-based follow-up was MyCareLink Smart. This uses a patient reader that manually interrogates the pacemaker in a similar way to previous programmers. This then transmits the pacemaker data via Bluetooth to the patient’s phone, which then transmits the data to CareLink via Wi-Fi connection or data services. Reproduced with permission from Medtronic.

percentages of adherence across all age groups suggest patients’ ability and desire to continue using RC.22

A further retrospective analysis was carried out on 156,426 patients in the US who were enrolled using the CareLink System between January 2012 and December 2016. The aim of the analysis was to assess patients’ compliance to scheduled transmissions in a real-world setting among different age groups. Over a mean follow-up of 3 years, compliance to scheduled remote monitoring since activation was 61.8% and sub-group analysis identified patients ≤60 years old (52.8%; 95% CI [52.1–53.5]) to be less compliant than patients >60 years (62.8%; 95% CI [62.6–63.1]). The outcome of this analysis is that less than two-thirds of patients are adherent to the follow-up regime at 3 years. This is clinically unacceptable in terms of comprehensive CIED follow-up. The system requires timely manual transmissions using the patient reader and so requires active engagement over the life of the patient and device. It is probable that this is the stage of the pathway that results in reduced engagement because it requires active action from the patient. With this in mind, increasing the automaticity of the system would likely result in more optimal follow-up adherence.23

**Next-generation Application-based Remote Monitoring**

The latest platform of pacemakers developed by Medtronic uses Bluetooth Low Energy to communicate with its programmer. Bluetooth Low Energy is different to the Bluetooth used in household items, such as speakers and hands-free headsets. These devices require high amounts of data transfer at fast rates. Bluetooth Low Energy is slower and for low volumes of data, so is perfectly suited to CIED interrogation. The current drain on the device is, as a consequence, approximately two-thirds of current energy drain used in historic device communication. As most current smartphones/tablets use Bluetooth for communication, this provides the perfect partnership.

MyCareLink Heart is a fully automated app-based RC system that communicates with Medtronic pacemakers using Bluetooth Low Energy. The compatible CIED is paired directly and automatically to the patient’s smartphone/tablet via the application. The patient’s device then transmits the data to CareLink securely via cellular network or landline internet connection. It uses the patient’s phone/tablet as a ‘pass-through’ device with no data being retained on the phone/tablet. Select data can then be passed back to the patient’s device via CareLink and is then visible on the MyCareLink Heart app (Figure 2).

This system requires the application to be open in the background on the patient’s device so that communication can occur, allowing passive data transfer, in contrast to active data transfer that requires action from the patient. The schedule of transmissions is directed by the clinic through the CareLink network. If a schedule is due and the patient does not have the application open, then a push notification will be sent to prompt action from the patient.

Patients’ interaction with the application provides a platform to prompt their consent on both passive and active transfer of data on an ongoing basis. Device and clinical alerts can be programmed on, so if there are any alerts the physician will receive notification of these outside of the usual follow-up regimen, with regular connectivity between the CIED and the patient’s device. These alerts include events related to lead impedance, low battery voltage, atrial tachycardia (AT)/AF burden, VT episodes, fast V rate during AT/AF, capture management and percentage V pacing.

The system has the facility for patients to make an additional transmission if required. To ensure that this facility is not used inappropriately the patient is prompted with “Does your clinic know that you are going to send a transmission?” Limited data are fed back to the MyCareLink Heart app, including battery longevity, activity levels determined by the accelerometer and the status of the patient’s transmission schedule. The application also allows patients to record vital signs and any symptoms on a daily basis. The data are not transmitted to CareLink but allow a record that the patient can show to their healthcare professional. There are education signposts within the application and also essential details about the patient’s device and leads that can act as their CIED identification card (Figure 3).
This next generation of app-based monitoring represents an example of Quantifying Self Hybrid Models (QSHMs), which combine features of patient reported outcomes measures (PROMs) and objective telemonitoring into a system that integrates passive data collection and active patient reporting. They help to overcome the unreliable subjectivity of PROMs and the absolute objectivity of telemonitoring alone. The use of QSHMs promotes patients’ enablement, and initial studies evaluating the impact of QSHMs in chronic disease management have been promising.24

A prospective randomised control trial conducted in Toronto, Canada, examined this in 110 patients with diabetes and uncontrolled systolic hypertension. Patients in the intervention group were provided with a home blood pressure (BP) telemonitoring system that provided self-care messages on the patients’ smartphones based on the averages of the transmitted readings. Patients in the control group were provided with a home BP monitoring system without the self-care messages. At 12 months, there was a significant reduction in the mean daytime systolic BP (−9.1 mmHg and −1.5 mmHg), and mean daytime diastolic BP (−4.6 mmHg and −1.3 mmHg) in the intervention group compared with the control group, respectively. In addition, 51% of the patients in the intervention group achieved the guideline recommended target BP (−9.1 mmHg and −1.3 mmHg) in comparison to 31% of the control group. There were no significant changes in the number or classes of antihypertensive medications at exit and there was no difference in the number of physicians’ office visits between both groups.25

**Expectations and Challenges**

Patients’ expectations from this technology would be to provide them with concise, clinically relevant information, promoting efficiency. The main concern would be overuse of this technology because of the increased generation of data. Initial experience with this next-generation application showed that after the introduction of notifications prompting patients to acknowledge unscheduled downloads and asking them if their healthcare practitioner was aware of them, most of the time they don’t go through with them, making a high volume of unscheduled downloads by the patients less likely. Another concern that would need to be addressed is healthcare practitioners’ responsibility. With the increased automaticity of the follow-up process with minimal – if any – action required by the patient, it is implied that more responsibility for the device follow-up is shifted to the patient to the healthcare practitioner/physician. This means that guidelines and pathways need to be implemented to react in timely manner to the downloaded data. It is also important to stress the fact that the system does not replace emergency care for unwell patients.

Physicians’ expectations from this new technology would be to provide them with more information on the status of their device, in particular battery longevity and status of the scheduled transmissions, which is fed back to them through the application.
BlueSync Field Evaluation

BlueSync technology is intended to enable more secure automatic wireless RM via the Medtronic CareLink network with security controls implemented to protect the integrity of the device functionality and protecting patient data. BlueSync field evaluation is an observational prospective study that started recruiting patients in April 2018, with 254 patients enrolled and paired with MyCareLink Heart app. This is a global study (NCT03518658) that includes 104 patients in Europe. The primary objective is to measure the percentage of CareLink quarterly scheduled transmissions successfully completed within a reasonable timeframe. Secondary objectives include patient compliance to pre-scheduled CareLink transmissions, patient adoption to remote monitoring with the new application and patients and healthcare practitioners perceived value and user experiences with the application.

Wireless Programming with BlueSync Technology

The security of data transmission and communication is always a concern in healthcare environments. Programmers are used in the operating environment at the time of CIED implantation and in the clinic if programming adjustments are required. Currently, there are no facilities in place that allow for remote programming of CIEDs. The programming system is comprised of three components with facilities in place that allow for remote programming of CIEDs. The system has rigorous security enhancements with multiple levels of encryption in the device, the programming communicator and the programmer.

Connectivity Status

Green check mark confirms your phone settings are appropriate for your heart device to connect to the app.

My Transmissions

Has information about transmissions sent from a patient’s heart device to their clinic.

My Symptom Journal

Used to create a log of symptoms to share with doctor at an in-office visit.

Education

Provides information about living with a heart device.

BlueSync Field Evaluation

BlueSync technology is intended to enable more secure automatic wireless RM via the Medtronic CareLink network with security controls implemented to protect the integrity of the device functionality and protecting patient data. BlueSync field evaluation is an observational prospective study that started recruiting patients in April 2018, with 254 patients enrolled and paired with MyCareLink Heart app. This is a global study (NCT03518658) that includes 104 patients in Europe. The primary objective is to measure the percentage of CareLink quarterly scheduled transmissions successfully completed within a reasonable timeframe. Secondary objectives include patient compliance to pre-scheduled CareLink transmissions, patient adoption to remote monitoring with the new application and patients and healthcare practitioners perceived value and user experiences with the application.

Wireless Programming with BlueSync Technology

The security of data transmission and communication is always a concern in healthcare environments. Programmers are used in the operating environment at the time of CIED implantation and in the clinic if programming adjustments are required. Currently, there are no facilities in place that allow for remote programming of CIEDs. The programming system is comprised of three components with facilities in place that allow for remote programming of CIEDs. The system has rigorous security enhancements with multiple levels of encryption in the device, the programming communicator and the programmer.

Conclusion

There has been a steady increase in the number of patients with CIEDs, imposing a significant burden on the already limited resources arising from their follow-up in CIED outpatient clinics. RC offers an opportunity to resolve some of the challenges associated with the delivery of effective follow-up by improving efficiency and patient engagement.

Database analyses have consistently shown improved survival rates in patients undergoing RC. They now represent the new standard of care replacing routine clinic interrogation. Current systems require a significant degree of patient interaction to ensure that follow-up schedules are maintained. Remote follow-up requires the physical act of the patient interrogating their CIED using a communicating device. The MyCareLink Heart system increases the automaticity of this concept by seamless Bluetooth communication between the patient’s CIED and their smartphone/tablet. Further prospective studies will evaluate the true value to both patients and healthcare professionals.

References:

1. WHO. Executive Board: 142nd session. Provisional agenda item 4.4. mHealth: use of appropriate digital technologies for public health. Geneva: WHO, 2017. https://apps.who.int/gb/ebwha/pdf_files/EB142/B142_20-en.pdf (accessed 10 February 2020).
2. WHO. Resolution WHA58, page 109. 58th World Health Assembly: Geneva: WHO, 2005.
3. Mobile fact sheet. Pew Research Center. https://www.pewresearch.org/internet/fact-sheet/mobile (accessed 10 February 2020).
4. Smith A. US Smartphone Use in 2015. Pew Research Center. April 2015. https://www.pewinternet.org/2015/04/01/us-smartphone-use-in-2015 (accessed 10 February 2020).
5. Xerox Corporation. New insights on value-based Care: Healthcare Attitudes: Xerox, 2016. https://www.baseinc.com/sites/default/files/xmrus/4Healthcare_attitudes-2016.pdf (accessed 10 February 2020).
6. WHO. Executive Board: 139th session. Provisional agenda item 6.6. mHealth – use of mobile wireless technologies for public health. Geneva: WHO, 2016. http://apps.who.int/gb/ebwha/pdf_files/EB139/B139_8-en.pdf (accessed 10 February 2020).
7. Borioni G, Auricchio A, Klersy C, et al. Healthcare personnel resource burden related to in-clinic follow-up of cardiovascular implantable electronic devices: a European Heart Rhythm Association and Eucomed joint survey. Europace 2011;13:1166–73. https://doi.org/10.1093/europace/euq296; PMID: 21340192.
8. Raathikainen MJ, Amar DG, Merkely B, et al. A decade of information on the use of cardiac implantable electronic devices and interventional electrophysiological procedures in the European Society of Cardiology Countries: 2017 report from the European Heart Rhythm Association. Europace
9. Burri H. Remote follow-up and continuous remote monitoring, distinguished. Europace 2013;15(Suppl 1):i14–i6. https://doi.org/10.1093/europace/eut207; PMID: 23737223.

10. Varma N, Epstein AE, Irimpen A, et al. Efficacy and safety of automatic remote monitoring for implantable cardioverter-defibrillator follow-up: the Lumos-T Safety Reduces Routine Office Device Follow-up (TRUST) trial. Circulation 2010;122:325–32. https://doi.org/10.1161/CIRCULATIONAHA.109.892405; PMID: 20423118.

11. Varma N, Michalski J, Stambler B, et al. Superiority of automatic remote monitoring compared with in-person evaluation for scheduled ICD follow-up in the TRUST trial-testing execution of the recommendations. Eur Heart J 2014;35:1345–52. https://doi.org/10.1093/eurheartj/ehu419; PMID: 22127418.

12. Crossley GH, Boyle A, Vitense H, et al. The clinical Evaluation of remote notification to reduce time to clinical Decision (CONNECT) trial: the value of wireless remote monitoring with automatic clinician alerts. J Am Coll Cardiol 2011;57:1811–9. https://doi.org/10.1016/j.jacc.2010.12.012; PMID: 21255955.

13. Guedon-Moreau L, Lacroix D, Sadoul N, et al. A randomized study of remote follow-up of implantable cardioverter-defibrillators: safety and efficacy report of the ECOST trial. Eur Heart J 2015;34:605–14. https://doi.org/10.1093/eurheartj/ehv485; PMID: 25402192.

14. Mital S, Piccini JP, Fischer A, et al. Increased adherence to remote monitoring is associated with reduced mortality in both pacemaker and defibrillator patients. Heart Rhythm Society 2014 Scientific Sessions, 8 May 2014, San Francisco, CA. Abstract LB03-I5.

15. Crossley GH, Chen J, Chsuicai W, et al. Clinical benefits of remote versus transtelephonic monitoring of implanted pacemakers. J Am Coll Cardiol 2009;54:2012–9. https://doi.org/10.1016/j.jacc.2009.10.001; PMID: 19926006.

16. Ldatapo I, Turakhia MP, Ryan MP, et al. Health care utilization and expenditures associated with remote monitoring in patients with implantable cardiac devices. Am J Cardiol 2016;117:1455–62. https://doi.org/10.1016/j.amjcard.2016.02.015; PMID: 26996767.

17. Saxon LA, Hayes DL, Gillam FR, et al. Long-term outcome after ICD and CRT implantation and influence of remote device follow-up: the AUDITUDe survival study. Circulation 2010;122:2359–67. https://doi.org/10.1161/CIRCULATIONAHA.109.963637; PMID: 21098452.

18. Varma N, Piccini JP, Snell J, et al. The relationship between level of adherence to automatic wireless remote monitoring and survival in pacemaker and defibrillator patients. J Am Coll Cardiol 2015;65:2607–10. https://doi.org/10.1016/j.jacc.2015.04.033; PMID: 25983008.

19. Slawter O, Varma N, Akar JG, et al. HRS expert consensus statement on remote interrogation and monitoring for cardiovascular implantable electronic devices. Heart Rhythm 2015;12:e69–100. https://doi.org/10.1016/j.hrtm.2015.05.008; PMID: 25981148.

20. Haughney J, Cotton P, Rosen JP, et al. The use of a modification of the patient enablement instrument in asthma. Prim Care Respir J 2007;16:99–102. https://doi.org/10.3132/pcrj.2007.0014; PMID: 17356786.

21. Taraki K, Vlites CA, Patel AS, et al. Success of pacemaker remote monitoring using app-based technology: does patient age matter? Pacific Electrophysiol 2016;41:1299–303. https://doi.org/10.1111/pac.13461; PMID: 30055013.

22. Taraki K, Zwebel S, Turakhia MP, et al. Compliance to remote monitoring of pacemakers: A US CARElink analysis. Heart Rhythm 2018;15(Suppl S Suppl 9):S90–640. Poster P-036-040.

23. Appelboom G, Sussman ES, Raphael P, et al. A critical assessment of approaches to outpatient monitoring. Curr Med Res Opin 2014;30:1363–4. https://doi.org/10.1185/03007995.2014.904774; PMID: 24627950.

24. Logan AG, Irvine MJ, McIsaac WI, et al. Effect of home blood pressure telemonitoring with self-care support on uncontrolled systolic hypertension in diabetics. Hypertension 2012;60:31–7. https://doi.org/10.1161/HYPERTENSIONAHA.111.188409; PMID: 22615116.